The pharmaceutical company ‘AstraZeneca’ has recently announced that, Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 inhibitor (SGLT2), has been now approved in the country of Japan for the treatment of the chronic kidney disease (CKD) in the adult people suffering with or without type-2 diabetes (T2D).
The approval from the ministry of health, labour and welfare (MHLW) of Japan has been based on the positive results from the phase 3 trial of the DAPA-CKD, and this decision of Japan’s MHLW has been followed by the designation of the priority review, which had been granted by the MHLW earlier in 2021.
The Chronic Kidney Disease has been a serious and progressive condition, which was defined by the decreased functioning of the kidney, and it has also been often associated with an increased risk of the heart disease of heart stroke, and this condition has also been affecting around 840 million people across the world.
Although, the rates of the diagnosis have been remaining very low as around 90 percent of the patients are now unaware that, they might be having the disease, and Forxiga has been the first ever medicine approved for the treatment of the chronic kidney disease in the country of Japan, and this condition has affected 840 million people across the world.
Naoki Kashihara, president of Society of Nephrology of Japan said, the DAPA-CKD has been the landmark trial, that has been demonstrating the unprecedented decrease in the risk for the chronic kidney disease patients that have or do not have type-2 diabetes, and this milestone of transformation is going to bring hope to many patients suffering from the chronic kidney disease in Japan.
Writing is a medium to express feelings and convey facts. A creative mind never rests in peace and this amazing platform gives me the freedom to write about what I like most.
I’ve been a writer/blogger for the last twelve years and have covered technology-related topics. However, I also have considerable years of experience in writing for various domains – Technology, Beauty, Fashion, Pharmaceutical, human psychology etc. Technology is my forte.
I’ve handled many interesting projects. Writing is my passion. As an author, I’ve learned a lot in my long journey of penning down my thoughts!
